Sun Pharma Fact Sheet, Sun Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sun Pharma Fact Sheet    (SUNP)


Tomorrow at 5pm: Get the details of India's #1 defence stock


Here is the latest financial fact sheet of Sun Pharma. For more details, see the Sun Pharma quarterly results and Sun Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

SUN PHARMA Price History

Price Rs 489.7
Mkt Cap Rs m 1,178,587
Vol '000 238.7
P/E X 461.1
P/CF X 23.7
EPS (TTM) Rs 1.1
% ch % 0.7
No. of shares m 2,406.75
% ch week % -2.7
% ch 1-mth % -2.8
% ch 12-mth % 20.7
52 week H/L Rs 564.9/315.2
(As on Oct 21, 2020 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SUN PHARMA Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
SUN PHARMA EQUITY SHARE DATA
High Rs1,0741,201842701679 
Low Rs570706572433375 
Sales per share (Unadj.) Rs132.3118.4131.6110.4121.1 
Earnings per share (Unadj.) Rs21.923.532.710.713.4 
Diluted earnings per shareRs18.923.532.610.713.3 
Cash flow per share (Unadj.) Rs27.727.837.917.020.7 
Dividends per share (Unadj.) Rs3.001.003.502.002.75 
Adj. dividends per shareRs2.581.003.491.992.74 
Dividend yield (eoy) %0.40.10.50.40.5 
Book value per share (Unadj.) Rs135.2137.1152.7159.7172.6 
Adj. book value per shareRs116.4137.0152.2159.2172.1 
Shares outstanding (eoy) m2,071.162,406.602,399.262,399.262,399.26 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x6.28.15.45.14.4 
Avg P/E ratio x37.540.621.753.039.4 
P/CF ratio (eoy) x29.734.318.633.425.5 
Price / Book Value ratio x6.17.04.63.53.1 
Dividend payout %13.74.310.718.720.6 
Avg Mkt Cap Rs m1,703,0112,294,8131,696,8771,360,0211,264,650 
No. of employees `000NA14.717.517.817.5 
Total wages/salary Rs m45,02647,72349,02353,67159,671 
Avg. sales/employee Rs ThNM19,317.218,028.314,890.916,608.1 
Avg. wages/employee Rs ThNM3,236.12,798.83,017.13,409.6 
Avg. net profit/employee Rs ThNM3,836.94,473.81,443.61,833.8 
SUN PHARMA INCOME DATA
Net Sales Rs m273,920284,870315,784264,895290,659 
Other income Rs m5,4776,5836,2328,38810,255 
Total revenues Rs m279,397291,453322,016273,282300,914 
Gross profit Rs m78,66781,583100,89356,08163,076 
Depreciation Rs m11,94710,37512,64814,99817,533 
Interest Rs m5,7905,2323,9985,1765,553 
Profit before tax Rs m66,40772,55890,47944,29550,246 
Minority Interest Rs m-9,3630000 
Prior Period Items Rs m-12615000 
Extraordinary Inc (Exp) Rs m-2,378-6,8520-9,505-12,144 
Tax Rs m9,1479,13812,1169,1106,009 
Profit after tax Rs m45,39456,58378,36325,67932,093 
Gross profit margin %28.728.631.921.221.7 
Effective tax rate %13.812.613.420.612.0 
Net profit margin %16.619.924.89.711.0 
SUN PHARMA BALANCE SHEET DATA
Current assets Rs m288,782299,413329,537316,359310,692 
Current liabilities Rs m153,294131,440178,870198,643173,396 
Net working cap to sales %49.559.047.744.447.2 
Current ratio x1.92.31.81.61.8 
Inventory Days Days7682799599 
Debtors Days Days688783108112 
Net fixed assets Rs m151,694180,477204,766213,178232,477 
Share capital Rs m2,0712,4072,3992,3992,399 
"Free" reserves Rs m278,009327,418363,997380,742411,691 
Net worth Rs m280,080329,825366,397383,141414,091 
Long term debt Rs m13,59831,10314,36117,72115,226 
Total assets Rs m501,601555,303614,102645,164646,938 
Interest coverage x12.514.923.69.610.0 
Debt to equity ratio x00.1000 
Sales to assets ratio x0.50.50.50.40.4 
Return on assets %10.211.113.44.85.8 
Return on equity %16.217.221.46.77.8 
Return on capital %20.519.724.810.010.2 
Exports to sales %16.913.9000 
Imports to sales %4.53.1000 
Exports (fob) Rs m46,23539,572000 
Imports (cif) Rs m12,2298,882000 
Fx inflow Rs m48,70642,17144,11851,40366,025 
Fx outflow Rs m25,56421,58324,48432,23338,610 
Net fx Rs m23,14220,58819,63419,17027,415 
SUN PHARMA CASH FLOW
From Operations Rs m 56,157 66,859 70,822 39,072 21,965 
From Investments Rs m -28,657 -43,716 -42,216 -33,708 -6,813 
From Financial Activity Rs m -11,865 -18,885 -22,854 -15,393 -27,305 
Net Cashflow Rs m 15,635 8,482 6,107 -7,359 -8,442 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 63.7%
Foreign collaborators 0.0%
Indian inst/Mut Fund 5.1%
FIIs 23.0%
ADR/GDR 0.0%
Free float 8.3%
Shareholders 133,026
Pledged promoter(s) holding 0.5%
 

Company Information

REGD OFF Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390 020
E-MAIL sunil.ajmera@sunpharma.com WEB www.sunpharma.com
TELEPHONE (022) 6696 9696 FAX (022) 2821 2010
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
AUDITOR Deloitte Haskins & Sells
CHM: Israel Makov COMP SEC: Sunil R. Ajmera YEAR OF INC: 1993 BSE CODE: 524715 FV (Rs): 1 DIV YIELD (%): 0.6

Read: SUN PHARMA 2018-19 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   NOVARTIS  J.B.CHEMICALS  ELDER PHARMA  PROCTER & GAMBLE HEALTH  IPCA LABS  

Compare SUN PHARMA With:   NOVARTIS  J.B.CHEMICALS  ELDER PHARMA  PROCTER & GAMBLE HEALTH  IPCA LABS  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  




Today's Market

Sensex Ends 163 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

It was indeed a volatile trading day for share markets in India today. After staging a gap-up opening, Indian share markets reversed gains.

Views on news

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

My Latest Stock Recommendation (Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC (Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer (Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUN PHARMA

SUN PHARMA - ADCOCK INGRAM COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS